Quantitative analysis for Kardigan Inc. Common Stock (KARD) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (32.0) (grade D). 27 signals analyzed (23 differentiated alt-data).
KARD stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-06-18 | $23.75 | $16.25 | $22.00 |
| 2026-06-26 | $24.54 | $21.88 | $23.60 |
| 2026-07-06 | $24.36 | $23.43 | $23.78 |
| 2026-07-13 | $24.38 | $22.72 | $23.53 |
| 2026-07-20 | $22.05 | $20.75 | $21.40 |
| 2026-07-27 | $21.73 | $20.17 | $21.23 |
| 2026-08-03 | $20.85 | $20.03 | $20.52 |
| 2026-08-10 | $21.83 | $20.31 | $21.16 |
| 2026-08-18 | $21.40 | $20.07 | $20.92 |
| 2026-08-25 | $21.38 | $20.51 | $20.92 |
| 2026-09-01 | $20.40 | $19.41 | $19.60 |
| 2026-09-09 | $22.00 | $19.62 | $19.68 |
How Kardigan Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
View all Health Care stocks by valuation and signals →
Kardigan Inc. Common Stock (KARD) scores Sell (32.0), and the composite conceals a 79-point disagreement between its dimensions. It is strongest on analyst consensus at 90, and weakest on competitive moat at 29 and technicals at 11. A stock can carry analyst consensus that high while technicals sits at 11; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 90 |
| competitive moat | 29 |
| technicals | 11 |
StoQuant analyzes 27 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Kardigan Inc. Common Stock (KARD): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/KARD"><img src="https://stoquant.com/badge/KARD.svg" alt="Kardigan Inc. Common Stock (KARD) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.